Agile Therapeutics focuses on advancing women's health through innovative contraceptive solutions, particularly with their flagship product, Twirla®. This product is a weekly hormonal birth control patch that delivers a low dose of estrogen and is designed for women with a body mass index (BMI) of less than 30 kg/m². Twirla® utilizes proprietary SkinFusion® Technology, which enhances drug administration and wearability, ensuring that the patch adheres effectively to the skin while delivering the necessary hormones. The formulation includes two key hormones: levonorgestrel (a progestin) and ethinyl estradiol (an estrogen), which work together to prevent pregnancy when used as directed.

The company emphasizes the importance of safety and efficacy, providing detailed prescribing information and warnings for potential users. Notably, Twirla® is not recommended for women with a BMI of 30 kg/m² or higher, as well as those with certain health conditions that may increase the risk of serious side effects, such as blood clots or cardiovascular issues. Agile Therapeutics is committed to ensuring that women have access to safe and effective contraceptive options, and their ongoing research and product development reflect this dedication to women's healthcare choices.

United States

Agile Therapeutics® is a forward-thinking women’s healthcare company dedicated to fulfilling the unmet needs of today’s women. Our product and product candidates are designed to offer women more freedom and flexibility through additional contraceptive options.

Urogenital Diseases

Agile Therapeutics

Contraceptive

Progestin and estrogen contraception

Twirla (levonorgestrel and ethinyl estradiol) transdermal system is a once-weekly combined hormonal contraceptive (CHC) patch that contains the active ingredients levonorgestrel (LNG), a type of progestin, and ethinyl estradiol (EE), a type of estrogen. Twirla is indicated for use as a method of contraception by women of reproductive potential with a body mass index (BMI) &lt; 30 kg/m2 for whom a combined hormonal contraceptive is appropriate to prevent pregnancy. Healthcare providers (HCPs) are encouraged to consider Twirla’s reduced efficacy in women with a BMI ≥ 25 to &lt;30 kg/m2 before prescribing.&nbsp; Twirla is contraindicated in women with a BMI ≥ 30 kg/m2. Twirla is designed to be applied once weekly for three weeks, followed by a week without a patch.

Twirla (levonorgestrel and ethinyl estradiol) transdermal system

Progestin-only contraception

Progestin-only contraceptive patch. Developed to meet broader contraceptive needs: Women who are breastfeeding, Women at higher risk of VTE (risk factors like smoking, age &gt; 35 years, VTE history, obesity)

Agile Therapeutics

Company Details